Clinical trials: Antisynthetase Syndrome, active
Myositis, Active Idiopathic Inflammatory Myopathy
A Study to Assess the Long-term Safety and Efficacy of a Subcutaneous Formulation of Efgartigimod in Adults With Active Idiopathic Inflammatory Myopathy
The main purpose of this study is to measure the long-term safety and tolerability of efgartigimod PH20 SC in adult participants with Idiopathic Inflammatory Myopathy (IIM) who previously participated in ARGX-113-2007.
- Conditions
- Myositis, Active Idiopathic Inflammatory Myopathy, Dermatomyositis, Polymyositis
- Trial name
- ALKIVIA+ (NCT05979441)
- Testing
- Efgartigimod PH20 SC
- Where
- 92 sites in United States, Argentina and 27 more
- Volunteers
- 240 people
- Sponsor
- argenx
Antisynthetase Syndrome
Descartes-08 in Autoantibody Myositis
This is a randomized, double-blind, placebo-controlled phase 2 study to evaluate the efficacy, safety and tolerability of an autologous T-cells expressing a chimeric antigen receptor (CAR) directed to B-Cell maturation antigen…
- Trial name
- NCT07391605
- Testing
- Descartes-08
- Where
- 4 sites in United States
- Volunteers
- 60 people
- Sponsor
- Cartesian Therapeutics
Inflammatory Myopathy
BCMA-CD19 cCAR-T for the Treatment of Refractory Inflammatory Myopathy
This single-arm, open-label, phase I trial evaluates the safety and tolerability of ICG318 CAR-T (BCMA-CD19-IL-15/IL15sushi cCAR T cells) in patients with refractory Idiopathic inflammatory myopathy (IIM).
- Trial name
- NCT07715136
- Testing
- ICG318, BCMA-CD19-IL-15/IL-15 sushi Compound CAR-T
- Where
- China
- Volunteers
- 10 people
- Sponsor
- iCell Gene Therapeutics
Antisynthetase Syndrome, Interstitial Lung Disease (ILD)
A Study on the Efficacy and Safety of JAK Inhibitors Versus Calcineurin Inhibitors as Initial Therapy for Interstitial Lung Disease Associated With Antisynthetase Syndrome
This study is a prospective investigation comparing the efficacy and safety of Janus kinase inhibitors versus calcineurin inhibitors as initial therapy for interstitial lung disease associated with antisynthetase syndrome.
- Trial name
- JAKCNIASSILD (NCT07406932)
- Testing
- JAK Inhibitor, Calcineurin Inhibitors (CNI)
- Where
- China
- Volunteers
- 80 people
- Sponsor
- China-Japan Friendship Hospital
Inflammatory Myopathy, Idiopathic, Dermatomyositis
Add-on Intravenous Immunoglobulins in Early Myositis
In patients with myositis early immunomodulation by intensive treatment ("hit-early/hit-hard" principle) may induce faster reduction of disease activity and prevent chronic disability.
- Conditions
- Inflammatory Myopathy, Idiopathic, Dermatomyositis, Antisynthetase Syndrome, Immune-Mediated Necrotizing Myopathy
- Trial name
- TIMEISMUSCLE (NCT05832034)
- Testing
- Immune Globulin Intravenous (Human)
- Where
- Netherlands
- Volunteers
- 44 people
- Sponsor
- Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Antisynthetase Syndrome, Rheumatoid Arthritis
An Exploratory Clinical Study of CD19 CAR NK Cells for the Treatment of Refractory Antisynthetase Antibody Syndrome and Rheumatoid Arthritis
A single-center, open-label dose-escalation design to evaluate the safety and efficacy of 3 infusions of anti CD19 CAR NK cells (KN5501), as well as the expansion and persistence of KN5501 in patients with refractory…
- Trial name
- NCT06613490
- Testing
- anti CD19 CAR NK cells
- Where
- China
- Volunteers
- 24 people
- Sponsor
- The First Affiliated Hospital with Nanjing Medical University
Idiopathic Inflammatory Myopathies
Optimizing Treatment on Idiopathic Inflammatory Myopathies
As a T2T, our patients with idiopathic inflammatory myopathies will receive pulse therapies with methyprednisolone and/or human intravenous immunoglobulin, or only methyprednisolone at disease onset.
- Trial name
- NCT03092180
- Testing
- Intravenous Infusion
- Where
- Brazil
- Volunteers
- 60 people
- Sponsor
- University of Sao Paulo